Jefferies Downgrades Mesoblast to Hold
Jefferies analyst David Stanton downgrades Mesoblast (NASDAQ:MESO) from Buy to Hold.
Why Leslie’s Shares Are Trading Lower By Over 9%? Here Are 60 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Biophytis S.A. (NASDAQ: BPTS) shares jumped 114% to $0.7496.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) rose 74.1% to $0.2115.
Workday, XPeng, Titan Machinery And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Wednesday. Here are some big stocks recording gains in today’s session.
Reported Late Tuesday, Mesoblast Announces Top-Line Long-Term Survival Results For Remestemcel-L From Its Pivotal Phase 3 Trial Through 4-Years In Children With Steroid-Refractory Acute Graft vs Host Disease
Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001
Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers
LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday’s Mid-Day Session
Gainers
LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
Piper Sandler Initiates Coverage On Mesoblast with Overweight Rating, Announces Price Target of $7
Piper Sandler analyst Edward Tenthoff initiates coverage on Mesoblast (NASDAQ:MESO) with a Overweight rating and announces Price Target of $7.
Short Volatility Alert: Mesoblast Limited
On Wednesday, shares of Mesoblast Limited (NASDAQ: MESO) experienced volatile short activity. After the activity, the stock price went up +2.77% to $3.34.
The overall sentiment for MESO has been Bearish.
Mesoblast Announced Single Intervention With Rexlemestrocel-l Improves Left Ventricular Ejection Fraction at 12 Months, Preceding Long-term Reduction in Major Adverse Cardiovascular Events
Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that treatment of HFrEF patients with rexlemestrocel-L, its allogeneic "off-the-shelf" product candidate for the treatment of chronic heart failure with reduced ejection fraction, resulted in greater improvement in the pre-specified analysis of left ventricular ejecti
